Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 11, 2007, Pages 1138-1144

  Canaparo, Roberto ^a   Finnström, Niklas ^b   Serpe, Loredana ^a   Nordmark, Anna ^b   Muntoni, Elisabetta ^a   Eandi, Mario ^a   Rane, Anders ^b   Zara, Gian Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ABCB1; CYP3A; Ileum; Jejunum; mRNA; P glycoprotein; Protein; Stomach

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; XENOBIOTIC AGENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENOTYPE; HUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE PREPARATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; ILEUM; ISOENZYMES; JEJUNUM; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RNA, MESSENGER; STOMACH;

EID: 34548695887     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04691.x     Document Type: Article

References (43)

1. de Wildt SN, Kearns GL, Leeder JS, den Anker JN. Cytochrome P450, 3A. Clin. Pharmacokinet. 1999 37 : 485 505.
2. Gellner K, Eiselt R, Hustert E et al. Genomic organization of the human CYP3A locus: Identification of a new, inducible CYP3A gene. Pharmacogenetics 2001 11 : 111 21.
3. Finnström N, Bjelfman C, Soderstrom TG et al. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Invest. 2001 31 : 880 6.
4. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2003 123 : 369 75.
5. Yaffe SJ, Rane A, Sjoqvist F, Boreus LO, Orrenius S. The presence of a monooxygenase system in human fetal liver microsomes. Life Sci. 1970 9 : 1189 200.
6. Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kanakubo Y. Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations. Biochem. Pharmacol. 1987 36 : 453 6.
7. Ladona MG, Lindstrom B, Thyr C, Dun-Ren P, Rane A. Differential fetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br. J. Clin. Pharmacol. 1991 32 : 295 302.
8. Hakkola J, Raunio H, Purkunen R et al. Cytochrome P450 3A expression in the human fetal liver: Evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol. Neonate 2001 80 : 193 201.
9. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999 39 : 361 98.
10. de Silva MG, Kantharidis P, Scherer SW et al. Physical mapping of a tandem duplication on the long arm of chromosome 7 associated with a multidrug resistant phenotype. Cancer Genet. Cytogenet. 1999 110 : 28 33.
11. Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in the first-pass metabolism overemphasized? Pharmacol. Rev. 1999 51 : 135 57.
12. Zhang Y, Benet LZ. The gut as a barrier to drug absorption. Clin. Pharmacokinet. 2001 40 : 159 68.
13. Becquemont L, Camus M, Eschwege V et al. Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. Fundam. Clin. Pharmacol. 2000 14 : 519 25.
14. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 1992 52 : 453 7.
15. Wu CY, Benet LZ, Hebert MF et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 1995 58 : 492 7.
16. Paine MF, Shen DD, Kunze KL et al. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 1996 60 : 14 24.
17. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab. Dispos. 1996 24 : 1121 3.
18. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996 24 : 796 801.
19. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001 27 : 383 91.
20. 450 gene expression in liver and blood in patients with suspected liver disease. Eur. J. Clin. Pharmacol. 2001 57 : 403 9.
21. Fakhoury M, Litalien C, Medard Y et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab. Dispos. 2005 33 : 1603 7.
22. Fasco MJ, Silkworth JB, Dunbar DA, Kaminsky LS. Rat small intestinal cytochromes P450 probed by warfarin metabolism. Mol. Pharmacol. 1993 43 : 226 33.
23. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clin. Pharmacol. Ther. 2004 75 : 172 83.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J. Biochem. 1951 193 : 265 75.
25. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl Acad. Sci. USA 1979 76 : 350 4.
26. Lacueva FJ, Teruel A, Calpena R et al. Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies. Histopathology 1998 32 : 328 34.
27. Fredericks WJ, Chen YF, Baker RM. Immunoblot detection of P-glycoprotein in human tumours and cell lines. Cancer Treat. Res. 1991 57 : 121 49.
28. Fukuen S, Fukuda T, Maune H et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 2002 12 : 331 4.
29. Kolars JC, Lown KS, Schmiedlin-Ren P et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994 4 : 247 59.
30. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995 36 : 259 67.
31. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 2000 25 : 169 93.
32. Paine MF, Khalighi M, Fisher JM et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 1997 283 : 1552 62.
33. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 1999 27 : 804 9.
34. Thörn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol. 2005 60 : 54 60.
35. Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 2000 12 : 3 12.
36. Westlind-Johnsson A, Malmebo S, Johansson A et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. 2003 31 : 755 61.
37. Lin YS, Dowling AL, Quigley SD et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 2002 62 : 162 72.
38. Lindell M, Karlsson MO, Lennernas H, Pahlman L, Lang MA. Variable expression of CYP and Pgp genes in the human small intestine. Eur. J. Clin. Invest. 2003 33 : 493 9.
39. Ozdemir V, Kalowa W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 2000 10 : 373 88.
40. Doherty MM, Charman WN. The mucosa of the small intestine: How clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet. 2002 41 : 235 53.
41. Mouly S, Paine MF. P-Glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res. 2003 20 : 1595 9.
42. Hoffmeyer S, Burk O, Von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 2000 97 : 3473 8.
43. Albertioni F, Gruber A, Arestrom I, Vitols S. Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia. Med. Oncol. 1995 12 : 79 86.